Skip to main content
. 2022 Nov 19;23(22):14383. doi: 10.3390/ijms232214383

Table 2.

The association of E-cadherin expression with FIGO stage of EOC patients.

Number of All Patients FIGO Number of Preserved/Positive Patients (%) Number of Reduced/Negative Patients (%) p Value Localization Cutoff [%] Ref.
80
I/II
III/IV		 ≥++
21 (72) *
20 (39)		 +
6 (21)
16 (31)		 −
3 (10)
14 (28)		 * <0.05 M 1 [25]
73 I
II
III
IV		 19 (70)
6 (60)
13 (39)
1 (33)		 8 (30) *
4 (40)
20 (61)
2 (67)		 * 0.017
(vs. FIGO IV)		 M+C Nd [26]
76 I
II
III
IV		 13 (48)
5 (50)
9 (25)
0 (0)		 14 (52) *
5 (50)
27(75)
3 (100)		 * 0.027
(vs. FIGO IV)		 M Nd [26]
74 I
II
III
IV		 2 (7)
1 (10)
3 (9)
0 (0)		 25 (93)
9 (90)
31 (91)
3(100)		 1.000 C Nd [26]
95 I
II
III
IV
I/II
III/IV		 39 (91)
3 (100)
62 (87)
12 (71)
42 (89)
74 (84)		 nd ns M 10 [32]
123 I/II
III/IV		 41 (65)
22 (37)		 0.002 M 10 [43]
282 I
II
III
IV		 27 (35)
10 (23)
36 (27)
5 (19)		 56 (65)
34 (77)
98 (73)
22 (81)		 0.12 M 5 [49]
50 I/II
III/IV		 8 (67)
12 (32) *		 4 (33)
26 (68) *		 0.044 NL 10 [51]
60 I/II
III/IV		 12 (67)
5 (12)		 nd <0.01 NL 25 [52]
75 I
II
III
IV		 116.9 ± 86.6 *
106.1 ± 67.8 **
101.0 ± 74.8 **
52.7 ± 15.0		 nd * ≤0.05
** ≤0.01
(vs. FIGO IV)		 C Nd [53]
300 I/II
III/IV		 80 (56)
11 (7)		 63 (44)
146 (93)		 <0.001 NL 5 [54]
77
I/II
III/IV		 ++
40 (83) *
17 (59) 		+
8 (17)
10 (34)		 −
0
2 (7)		 * 0.05 NL 1 [55]
68
I
II
III
IV		 ++
10 (27)
3 (30)
9 (50) *
0		 +
19 (51)
5 (50)
6 (33)
1 (33)		 −
8 (22)
2 (20)
3 (17)
2 (67)		 * <0.01 NL Nd [56]
64 I
II
III
IV		 nd 5 (42)
2 (40)
12 (27)
0		 0.63 M 25 [57]
46 I/II
III/IV		 14 (70)
15 (53)		 6 (30)
13 (46)		 0.35 NL 10 [58]

Nd—no data; ns—not significant; “−“ no E-cadherin immunoreactivity; “+” low E-cadherin immunoreactivity; “++” high E-cadherin immunoreactivity; *, **—statistical significance; NL—not localized; M—membranous; C—cytoplasmic.